patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_899768 | REC_0003101 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.4 | 61 | female | 0 | 0 | 6.1 | 4 | osimertinib 80 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:57.609679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719823 | REC_0003102 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 17 | 1.7 | 70 | female | 2 | 84 | 5.2 | 0 | carboplatin + paclitaxel + pembrolizumab | 40.6 | false | MSS | 2026-03-15T05:35:57.609912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792155 | REC_0003103 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 17.9 | 50 | female | 0 | 11 | 4.6 | 2 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:57.610148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640672 | REC_0003104 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 13.1 | 54 | female | 0 | 11 | 3.8 | 4 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:35:57.610382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314927 | REC_0003105 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 21.5 | 61 | female | 1 | 17 | 7 | 5 | sotorasib 960 mg daily | 7 | true | MSS | 2026-03-15T05:35:57.610619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510344 | REC_0003106 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.9 | 74 | male | 2 | 13 | 4.8 | 9 | sotorasib 960 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:57.610852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147928 | REC_0003107 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 5 | 54 | female | 0 | 50 | 6.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:35:57.611082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650842 | REC_0003108 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 18.7 | 76 | female | 2 | 19 | 4.9 | 0 | sotorasib 960 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:35:57.611370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_781919 | REC_0003109 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.5 | 78 | female | 2 | 13 | 6.4 | 8 | pembrolizumab 200 mg q3w | 6.1 | true | MSS | 2026-03-15T05:35:57.611603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349637 | REC_0003110 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 3.6 | 73 | female | 1 | 64 | 3.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:35:57.611833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938376 | REC_0003111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9.3 | 67 | female | 1 | 11 | 5.4 | 1 | alectinib 600 mg BID | 23.6 | false | MSS | 2026-03-15T05:35:57.612064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693861 | REC_0003112 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10 | 64 | male | 0 | 26 | 3.9 | 5 | osimertinib 80 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.612336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_378397 | REC_0003113 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 8 | 75 | female | 3 | 30 | 4.3 | 4 | sotorasib 960 mg daily | 10.2 | false | MSS | 2026-03-15T05:35:57.612573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358175 | REC_0003114 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 19.8 | 70 | male | 1 | 20 | 5.8 | 6 | sotorasib 960 mg daily | 7.4 | true | MSI-H | 2026-03-15T05:35:57.612818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647220 | REC_0003115 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.7 | 63 | female | 0 | 14 | 6.4 | 2 | alectinib 600 mg BID | 21.8 | false | MSS | 2026-03-15T05:35:57.613062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164079 | REC_0003116 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.4 | 64 | female | 1 | 70 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.613295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253739 | REC_0003117 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 5.9 | 87 | female | 1 | 15 | 5.8 | 1 | pembrolizumab 200 mg q3w | 17.8 | false | MSS | 2026-03-15T05:35:57.613524+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367792 | REC_0003118 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.8 | 59 | male | 0 | 27 | 5.5 | 5 | entrectinib 600 mg daily | 7.3 | true | MSI-H | 2026-03-15T05:35:57.613759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208846 | REC_0003119 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.2 | 66 | female | 0 | 41 | 7.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:57.613989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932421 | REC_0003120 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.7 | 66 | female | 0 | 31 | 5 | 6 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:57.614222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729658 | REC_0003121 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.8 | 68 | male | 1 | 56 | 4.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:57.614523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577152 | REC_0003122 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.3 | 67 | female | 1 | 25 | 4.7 | 4 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:57.614762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529865 | REC_0003123 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 8 | 79 | female | 0 | 13 | 4.6 | 6 | pembrolizumab 200 mg q3w | 6.5 | true | MSS | 2026-03-15T05:35:57.614991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762727 | REC_0003124 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.7 | 75 | female | 1 | 16 | 6 | 5 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:35:57.615223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879863 | REC_0003125 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 6.4 | 73 | female | 2 | 7 | 5.2 | 2 | entrectinib 600 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:57.615454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826042 | REC_0003126 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 3.8 | 69 | female | 1 | 21 | 5.2 | 9 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:57.615681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380461 | REC_0003127 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 7 | 55 | male | 1 | 59 | 7.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.6 | false | MSS | 2026-03-15T05:35:57.615914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767989 | REC_0003128 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 4.5 | 73 | female | 0 | 32 | 6.3 | 1 | osimertinib 80 mg daily | 25.8 | true | MSS | 2026-03-15T05:35:57.616239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130993 | REC_0003129 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 8.9 | 70 | female | 0 | 12 | 7.4 | 5 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.616489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762218 | REC_0003130 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 6.3 | 72 | female | 1 | 19 | 7.1 | 7 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.616727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323105 | REC_0003131 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.2 | 63 | female | 0 | 24 | 4 | 6 | entrectinib 600 mg daily | 14.2 | false | MSI-H | 2026-03-15T05:35:57.616967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149250 | REC_0003132 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 6.4 | 68 | male | 0 | 43 | 4.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 18 | false | MSS | 2026-03-15T05:35:57.617200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_522518 | REC_0003133 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 13.5 | 83 | male | 1 | 27 | 5.2 | 2 | alectinib 600 mg BID | 15.6 | false | MSS | 2026-03-15T05:35:57.617437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704225 | REC_0003134 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 35 | 9.4 | 71 | female | 2 | 27 | 6 | 1 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.617739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709288 | REC_0003135 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.1 | 71 | male | 0 | 13 | 7 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:35:57.617980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701323 | REC_0003136 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 12 | 49 | female | 0 | 0 | 5.4 | 1 | osimertinib 80 mg daily | 23.7 | false | MSS | 2026-03-15T05:35:57.618219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775353 | REC_0003137 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 32 | 13.8 | 69 | female | 0 | 13 | 6.5 | 0 | osimertinib 80 mg daily | 45.2 | true | MSI-H | 2026-03-15T05:35:57.618457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227073 | REC_0003138 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 6.6 | 63 | female | 0 | 11 | 5.3 | 7 | pembrolizumab 200 mg q3w | 18.7 | false | MSS | 2026-03-15T05:35:57.618693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863389 | REC_0003139 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.4 | 59 | female | 1 | 12 | 7 | 10 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:57.618931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446362 | REC_0003140 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.4 | 66 | male | 0 | 12 | 6.3 | 7 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:57.619164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540311 | REC_0003141 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 11.4 | 77 | female | 1 | 10 | 7 | 7 | alectinib 600 mg BID | 9.7 | true | MSI-H | 2026-03-15T05:35:57.619404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774653 | REC_0003142 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 14.4 | 61 | male | 1 | 19 | 4.2 | 6 | sotorasib 960 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:57.619646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578229 | REC_0003143 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 8.4 | 60 | female | 0 | 44 | 6.2 | 7 | pembrolizumab 200 mg q3w | 6.5 | false | MSS | 2026-03-15T05:35:57.619882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829391 | REC_0003144 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 14 | 59 | male | 1 | 14 | 5 | 4 | pembrolizumab 200 mg q3w | 11.5 | false | MSS | 2026-03-15T05:35:57.620189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704652 | REC_0003145 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 5.2 | 68 | female | 1 | 24 | 5.6 | 6 | sotorasib 960 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:57.620442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_707464 | REC_0003146 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5 | 70 | female | 1 | 37 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.6 | false | MSS | 2026-03-15T05:35:57.620689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571380 | REC_0003147 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.9 | 65 | male | 1 | 21 | 7.5 | 1 | sotorasib 960 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:57.621063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158239 | REC_0003148 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.8 | 59 | male | 0 | 60 | 8.2 | 5 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:35:57.621315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161659 | REC_0003149 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.7 | 74 | female | 2 | 21 | 3.7 | 5 | alectinib 600 mg BID | 4.5 | false | MSS | 2026-03-15T05:35:57.621556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282827 | REC_0003150 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 16.9 | 87 | female | 1 | 13 | 7.9 | 5 | alectinib 600 mg BID | 11.1 | false | MSI-H | 2026-03-15T05:35:57.621797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_181751 | REC_0003151 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.8 | 64 | female | 0 | 34 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.2 | false | MSS | 2026-03-15T05:35:57.622045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563318 | REC_0003152 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 8.8 | 80 | female | 2 | 32 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.2 | false | MSS | 2026-03-15T05:35:57.622299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_516327 | REC_0003153 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 7.9 | 68 | female | 1 | 15 | 3.4 | 2 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:57.622542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648499 | REC_0003154 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 7.9 | 68 | female | 0 | 11 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 30.2 | true | MSS | 2026-03-15T05:35:57.622776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991613 | REC_0003155 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 9 | 50 | female | 0 | 19 | 3.6 | 2 | sotorasib 960 mg daily | 19.8 | true | MSS | 2026-03-15T05:35:57.623012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173971 | REC_0003156 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 5.2 | 59 | female | 0 | 7 | 6.3 | 6 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:57.623247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760929 | REC_0003157 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 14.1 | 60 | female | 1 | 2 | 3.4 | 2 | osimertinib 80 mg daily | 26.2 | false | MSS | 2026-03-15T05:35:57.623485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985640 | REC_0003158 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 13.6 | 68 | female | 1 | 15 | 6.9 | 1 | pembrolizumab 200 mg q3w | 28.5 | true | MSS | 2026-03-15T05:35:57.623723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700002 | REC_0003159 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.7 | 73 | female | 2 | 19 | 4.6 | 1 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:35:57.623958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507657 | REC_0003160 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 10.1 | 71 | female | 2 | 17 | 5.4 | 6 | sotorasib 960 mg daily | 7.6 | true | MSI-H | 2026-03-15T05:35:57.624403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826787 | REC_0003161 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 15 | 9.2 | 50 | female | 0 | 11 | 6.2 | 1 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.624656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763793 | REC_0003162 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 12.9 | 59 | female | 1 | 9 | 6.8 | 6 | pembrolizumab 200 mg q3w | 6.9 | false | MSI-H | 2026-03-15T05:35:57.624897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726834 | REC_0003163 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 11.3 | 60 | male | 1 | 19 | 5 | 7 | pembrolizumab 200 mg q3w | 8.9 | false | MSS | 2026-03-15T05:35:57.625138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475364 | REC_0003164 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 32 | 6 | 83 | female | 1 | 28 | 4.5 | 3 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:57.625369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587699 | REC_0003165 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.2 | 71 | female | 0 | 66 | 4.8 | 7 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:35:57.625605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760342 | REC_0003166 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13.1 | 84 | female | 0 | 15 | 4.9 | 5 | entrectinib 600 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:57.625838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806481 | REC_0003167 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 8.1 | 59 | female | 1 | 45 | 5.7 | 4 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:57.626070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406562 | REC_0003168 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 13.3 | 79 | female | 1 | 15 | 5 | 1 | entrectinib 600 mg daily | 22.2 | true | MSS | 2026-03-15T05:35:57.626302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_912965 | REC_0003169 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 32 | 4.2 | 66 | female | 0 | 51 | 5.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 37 | false | MSS | 2026-03-15T05:35:57.626531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721019 | REC_0003170 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 12.3 | 77 | female | 2 | 13 | 7.6 | 4 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.626764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293075 | REC_0003171 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.4 | 60 | female | 0 | 22 | 4.2 | 2 | sotorasib 960 mg daily | 28.5 | true | MSS | 2026-03-15T05:35:57.627002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722524 | REC_0003172 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 13 | 11.8 | 80 | male | 1 | 21 | 5.5 | 6 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:57.627238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565721 | REC_0003173 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 17.5 | 72 | female | 1 | 7 | 2.7 | 1 | sotorasib 960 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:57.627550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997025 | REC_0003174 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 13 | 7.2 | 69 | male | 0 | 66 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.6 | false | MSS | 2026-03-15T05:35:57.627788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499585 | REC_0003175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 14.8 | 82 | female | 2 | 3 | 7.1 | 5 | entrectinib 600 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:57.628022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972227 | REC_0003176 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 15.2 | 64 | male | 0 | 13 | 4.2 | 8 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.628325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420037 | REC_0003177 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 8.6 | 76 | female | 2 | 14 | 7.1 | 2 | entrectinib 600 mg daily | 27.3 | false | MSS | 2026-03-15T05:35:57.628570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514757 | REC_0003178 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 12 | 55 | female | 0 | 10 | 6.6 | 2 | entrectinib 600 mg daily | 28.8 | true | MSS | 2026-03-15T05:35:57.628811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334637 | REC_0003179 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 7.7 | 77 | female | 1 | 51 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.9 | false | MSS | 2026-03-15T05:35:57.629043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201111 | REC_0003180 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 13.1 | 61 | male | 1 | 26 | 5.3 | 5 | pembrolizumab 200 mg q3w | 17.2 | true | MSI-H | 2026-03-15T05:35:57.629284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_927863 | REC_0003181 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 9.6 | 79 | female | 1 | 54 | 7 | 1 | pembrolizumab 200 mg q3w | 20.3 | false | MSS | 2026-03-15T05:35:57.629515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467405 | REC_0003182 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 15.8 | 55 | female | 1 | 7 | 6.2 | 2 | osimertinib 80 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.629750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394862 | REC_0003183 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 13.4 | 62 | female | 0 | 14 | 4.9 | 7 | sotorasib 960 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:57.629986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817666 | REC_0003184 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 36 | 11.2 | 66 | female | 0 | 11 | 5 | 7 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:57.630218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690807 | REC_0003185 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.1 | 72 | female | 2 | 24 | 2.9 | 6 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:35:57.630449+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188612 | REC_0003186 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 8.9 | 62 | female | 0 | 14 | 5.3 | 6 | entrectinib 600 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.630750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906783 | REC_0003187 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 9.2 | 56 | female | 1 | 27 | 6.6 | 6 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:57.630995+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515630 | REC_0003188 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 7.6 | 73 | female | 1 | 17 | 4.5 | 6 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.631224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458657 | REC_0003189 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 14.2 | 56 | female | 1 | 13 | 7.3 | 1 | entrectinib 600 mg daily | 19.3 | true | MSI-H | 2026-03-15T05:35:57.631463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114847 | REC_0003190 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 66 | female | 0 | 55 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.2 | true | MSS | 2026-03-15T05:35:57.631691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989662 | REC_0003191 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.3 | 44 | male | 0 | 9 | 5.2 | 5 | alectinib 600 mg BID | 11.7 | true | MSI-H | 2026-03-15T05:35:57.631930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846681 | REC_0003192 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.4 | 67 | female | 1 | 15 | 5 | 5 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:57.632212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944507 | REC_0003193 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 7.1 | 79 | female | 1 | 14 | 7.8 | 5 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:57.632447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718125 | REC_0003194 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 9.3 | 70 | female | 1 | 21 | 4.4 | 5 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:35:57.632682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400824 | REC_0003195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 4.4 | 51 | male | 0 | 35 | 4 | 7 | pembrolizumab 200 mg q3w | 6.2 | true | MSS | 2026-03-15T05:35:57.632916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690039 | REC_0003196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 13.6 | 78 | female | 2 | 13 | 5.1 | 7 | osimertinib 80 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:57.633151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560398 | REC_0003197 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 9.5 | 58 | female | 1 | 10 | 3.9 | 1 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:57.633383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570635 | REC_0003198 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 11 | 70 | female | 1 | 23 | 6.1 | 6 | sotorasib 960 mg daily | 9.5 | true | MSI-H | 2026-03-15T05:35:57.633615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982601 | REC_0003199 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 11.6 | 87 | female | 2 | 0 | 3.9 | 7 | alectinib 600 mg BID | 10.3 | true | MSI-H | 2026-03-15T05:35:57.633916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_417038 | REC_0003200 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.2 | 74 | female | 1 | 5 | 4.8 | 1 | osimertinib 80 mg daily | 27.5 | true | MSS | 2026-03-15T05:35:57.634159+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.